To account for the unique metabotype dependent on the driver mutation for NSCLC, we screened for only lipid species satisfying both the abovementioned criteria for “benign vs EGFR mutant” and “benign vs non-EGFR mutants” comparisons as candidate malignancy markers (Table 2). This evidence concerns the gene EGFR and non-small cell lung carcinoma.